Herantis Pharma Plc · OMXHEX:HRTIS

Herantis Pharma — Investor Presentation (September 2023)

14 slides from Herantis Pharma's investor presentation, September 2023

  1. Slide 1: Company presentation September 2023

    Company presentation September 2023 Clinical-stage company developing disease-modifying treatment for Parkinson’s disease www.herantis.com © HERANTIS PHARMA Plc. All rights reserved.

  2. Slide 2: Forward-looking statement

    Forward-looking statement This company presentation includes forward-looking statements which are not historical facts but statements regarding future expectations instead. These forward-looking statements include without limitation, those regarding Herantis’ future financial position and results of

  3. Slide 3: Herantis – at a glance

    Herantis – at a glance Developing disease-modifying treatment to address the unmet clinical need in Parkinson’s disease and other neurodegenerative diseases Lead asset HER-096 is a small engineered peptide molecule with a unique mechanism of action and subcutaneous injection as an easy route of admi

  4. Slide 4: The unmet clinical need in Parkinson's disease

    The unmet clinical need in Parkinson’s disease BLOOD-BRAIN BARRIER (BBB) PARKINSON’S DISEASE (PD) CURRENT TREATMENTS CANNOT PROTECTS THE BRAIN – DIFFICULT TO • Degeneration of dopaminergic nerve STOP THE PROGRESSION OF PD DELIVER DRUGS TO THE TARGET TISSUE cells in mid brain cause severe motor • For

  5. Slide 5: HER-096 is a perfect drug candidate for Parkinson's disease

    HER-096 is a perfect drug candidate for Parkinson’s disease • Designed based on the active site of CDNF, a known ER protein and unfolded protein response (UPR) modulator HER-096 HER-096 • Restores proteostasis and reduces neuroinflammation • Synthetic peptidomimetic molecule, straightforward CMC OPT

  6. Slide 6: HER-096: A unique MoA targets Unfolded Protein Response (UPR) pathway

    HER-096: A unique MoA targets Unfolded Protein Response (UPR) pathway 6 www.herantis.com © HERANTIS PHARMA Plc. All rights reserved.

  7. Slide 7: HER-096 Improves Motor Function in the Mouse Synucleinopathy Model

    HER-096 Improves Motor Function in the Mouse Synucleinopathy Model Mouse bar test to observe motor coordination • Mouse walks from right to left CLICK BELOW TO SEE THE VIDEO ON YOUTUBE • Longer walking time corresponds to https://youtu.be/L3WmkhP2Opw compromised motor coordination • Video still imag

  8. Slide 8: Therapeutic Hypothesis for HER-096

    Therapeutic Hypothesis for HER-096 • HER-096 promotes neuronal survival and functional recovery under prolonged stress conditions 1. Reduced endoplasmic reticulum (ER) stress level by modulation of the unfolded protein response (UPR) pathway signalling 2. Reduced accumulation and toxicity of misfold

  9. Slide 9: HER-096 Phase 1a clinical trial in healthy volunteers

    HER-096 Phase 1a clinical trial in healthy volunteers Part 1: Part 2 (ongoing): Male, age 20-45 years Male & female, age >50 years Objectives: SAD Dose- • Safety and tolerability (single dose) level X=6 2+6M • Blood-brain barrier (BBB) penetration • Exploratory biomarkers SAD Dose- Single dose, adap

  10. Slide 10: Business highlights 2023

    Business highlights 2023 Regulatory approval First healthy Start of dosing of healthy (CTA) to start a HER-096 volunteer dosed in volunteers in part 2 of Phase 1a clinical trial. the HER-096 Phase HER-096 clinical Phase 1a trial – part 1. 1a trial Q1 Q2 Q3 EIC Accelerator grant agreement signed. Her

  11. Slide 11: We have joined Herantis to develop therapies for neurodegenerative diseases

    We have joined Herantis to develop therapies for those who are suffering from neurodegenerative diseases Management team Board of Directors Antti Vuolanto, D.Sc Timo Veromaa, MD, Hilde Furberg Mats Thorén Tone Kvåle CEO PhD, eMBA CFO Chairman Henri Huttunen, PhD Aki Prihti Frans Wuite, CSO MD, MBA 1

  12. Slide 12: Scientific Advisory Board of global industry and academic leaders

    Scientific Advisory Board of global industry and academic leaders • Anders Gersel Pedersen, M.D., Ph.D. • Daniele Bravi, M.D., Ph.D. • Chairman of the Board • Specialist Neurologist in movement • Globally renowned and respected expert in CNS disorders drug development. Previously Executive Vice • Re

  13. Slide 13: Herantis investment proposition

    Herantis investment proposition • HER-096 has the potential to become a therapy for Parkinson’s disease Lead asset with a unique, disease modifying Mechanism of Action • 10 million patients globally Market • Unmet need: no disease modifying therapies for Parkinson’s disease today • Multi-billion EUR

  14. Slide 14: Contact details

    Contact details CEO Antti Vuolanto, [email protected] CFO Tone Kvåle, [email protected] www.herantis.com © HERANTIS PHARMA Plc. All rights reserved.

Herantis Pharma — Investor Presentation (September 2023) on 6ix